How Hard to Chase Blood Pressure After Thrombolysis, Now That Intensive Lowering Lost Its Case
A patient's pressure stays elevated after a clean thrombolytic run, and the instinct to keep pushing it down runs straight into a large trial that found intensive lowering did prevent bleeds — without improving a single point of function.
S.K., a 71-year-old woman who still keeps her own vegetable garden and cans tomatoes every August, developed sudden right-sided weakness and word-finding difficulty while weeding at 2:15pm. Her daughter, visiting for the afternoon, called 911 immediately; she arrived at the hospital by 2:52pm with an NIHSS of 9 and was treated with alteplase within the standard window, her pressure lowered from 198/104 to 176/92 with labetalol boluses before the infusion started, clearing the pretreatment 185/110 threshold with room to spare. Her only known medical history is hypertension, treated inconsistently — she admits to skipping her amlodipine "most weeks, if I'm being honest" — and she has never had a stroke or a bleed before today.
Twenty hours after the infusion finished, her repeat CT shows no hemorrhagic transformation and her exam has meaningfully improved, NIHSS down to 4. Her blood pressure, though, has crept back up over the overnight hours and now sits at 178/96, just under the pretreatment threshold but well above what would be considered a normal target in an otherwise healthy adult. The overnight nurse has already asked twice whether to start a nicardipine drip to bring it down further, and the answer isn't as automatic as it might sound. ENCHANTED, the largest trial to test this exact question — intensive blood pressure lowering after thrombolysis, target 130-140 systolic within an hour, against guideline-standard management — found no improvement in functional outcome from the more aggressive strategy. What it did find complicates the picture rather than settling it: intracranial hemorrhage of any kind was significantly less frequent in the intensively treated arm, 14.8% against 18.7%, a real reduction in the exact complication the strategy was designed to prevent — which then failed to translate into a single point of functional benefit. Her own creatinine this morning is 1.3, up slightly from a baseline of 1.1, a reminder that she has a second organ whose perfusion also depends on the number being lowered, and that a trial finding no functional gain gives no reason to spend that margin chasing one.
On rounds, twenty hours after the infusion
I wouldn't start the nicardipine drip. Treat if she crosses 180/105 again, otherwise let this ride. ENCHANTED randomized more than two thousand patients to exactly this question — intensive lowering to 130-140 within an hour versus guideline-standard care after thrombolysis — and found no improvement in functional outcome from pushing harder. It's worth being precise about what it did find, because it cuts both ways: fewer intracranial hemorrhages in the intensive arm, 14.8% against 18.7%. It prevented bleeds and still didn't move function. That's a strong argument that chasing the number isn't what helps her.
I hear the trial result, but a pressure sitting at 178 for going on eighteen hours in someone whose vessel wall just went through reperfusion isn't nothing either — the observational literature on sustained post-thrombolysis hypertension and hemorrhagic transformation predates ENCHANTED and isn't erased by it. I'd want to bring her down somewhat, even if not all the way to ENCHANTED's intensive target.
A neutral trial on one specific aggressive protocol doesn't automatically mean "do nothing" is the only alternative reading.
You're right that it reduced hemorrhage without helping function, and I'd add the wrinkle that makes that less paradoxical than it sounds: ENCHANTED only ever separated its arms by about 6mmHg over 24 hours, 144 against 150. That's a thin test of a target. So I don't read it as proof that 130-140 is wrong in principle — I read it as a trial that never really got there.
But that's a hypothesis about why the trial came out neutral, not a reason to override what it actually found. The bottom-line, primary functional-outcome result was neutral, full stop, and that's the number that should set tonight's target, not a reinterpretation of the mechanism behind it. Permissive strategy, treat only above 180/105 unless something changes.
Agreed: permissive strategy overnight, treating only if systolic pressure exceeds 180/105 or a new focal deficit appears, rather than starting nicardipine at 178/96. Her creatinine will be rechecked in the morning, and her home amlodipine will be resumed once she's tolerating oral medications, with a real conversation about adherence before discharge.
Not agreed: the cardiologist remains genuinely uneasy leaving a sustained elevated pressure unaddressed this long after reperfusion, even without a positive trial specifically supporting intervention at her exact number, and said so directly rather than simply deferring to the trial data. The plan holds for tonight; nobody claimed the disagreement was resolved by it.